

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “**Meeting**”) of China NT Pharma Group Company Limited (the “**Company**”) will be held on Monday, 9 November 2026, 11 a.m. at Unit 2102, 21/F, West Tower, Shun Tak Centre, 168–200 Connaught Road Central, Hong Kong for the purpose of considering and, if thought fit, passing with or without amendments, the following resolutions of the Company:

ORDINARY RESOLUTIONS

1. To consider and to approve the appointment of HLB Hodgson Impey Cheng Limited as the auditor of the Company with effect from the passing of this resolution, to hold office until the conclusion of the next annual general meeting of the Company, and to authorise the board of directors of the Company to determine their remuneration.

Yours faithfully,
For and on behalf of
China NT Pharma Group Company Limited
Ng Tit
Chairman of the Board

Hong Kong, 21 October 2026

Notes:

1. Details of the above resolutions is set out in the circular of the Company dated 21 October 2026.
2. A member entitled to attend and vote at the Meeting is entitled to appoint one or more proxy to attend and, subject to the provisions of the articles of association of the Company, to vote on his/her/its behalf. A proxy need not be a member of the Company but must be present in person at the Meeting to represent the member. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.
3. A form of proxy for use at the Meeting is enclosed. Whether or not you intend to attend the Meeting in person, you are encouraged to complete and return the enclosed form of proxy in accordance with the instructions printed thereon. Completion and return of a form of proxy will not preclude a member from attending in person and voting at the Meeting or any adjournment thereof, should he/she/it so wish.

4. In the case of joint holders, the signature of any one holder will be sufficient but the names of all the joint holders should be stated. Where there are joint holders of any share of the Company, any one of such joint holders may vote at the meeting, either in person or by proxy, in respect of such share as if he/she were solely entitled thereto, but if more than one of such joint holders be present at the meeting, the vote of the senior who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint holders, and for this purpose seniority shall be determined as that one of the said persons so present whose name stands first on the register of members in respect of such share shall alone be entitled to vote in respect thereof.
5. In order to be valid, the form of proxy, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 48 hours before the time appointed for holding the Meeting or any adjournment thereof.
6. The register of members of the Company will be closed from 4 November 2026 to 9 November 2026 (both days inclusive), during which period no transfer of shares will be effected. In order to qualify for the entitlement to attend and vote at the above meeting, all transfer forms accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on 3 November 2026 for registration.
7. If typhoon signal No. 8 or above, or a "black" rainstorm warning is in effect any time after 7:00 a.m. on the date of the Meeting, the meeting will be postponed. The Company will publish a circular on the website of the Company at <https://www.ntpharma.com> and on the Stock Exchange website at <http://www.hkexnews.com> to notify shareholders of the Company of the date, time and place of the rescheduled meeting.
8. As at the date hereof, the Board comprised:

Executive Directors:

Mr. Ng Tit (*Chairman*)
Ms. Ng Anna Ching Mei

Non-executive Directors:

Dr. Qian Wei
Ms. Chin Yu
Mr. Lou Yongbin

Independent non-executive Directors:

Mr. Yu Tze Shan Hailson
Mr. Kwok Che Chung
Dr. Zhao Yubiao